Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026
On February 26, 2026, Jefferies maintained a Buy for Viridian Therapeutics, Inc. and raised its price target to $45, marking the lead development in recent coverage. The focus here is the VRDN analyst rating, which now shows two notable firms keeping positive stances the same day. Evercore ISI also maintained Outperform and added VRDN to its TAP list on the same date. These parallel actions suggest continued analyst conviction rather than a change in sentiment, and they matter for investors watching biotech catalysts and price momentum.
VRDN analyst rating: Jefferies maintains Buy and raises PT to $45
Jefferies on February 26, 2026 kept a Buy rating for Viridian Therapeutics and raised its price target to $45. That action followed the firm’s reassessment of program milestones and potential commercial value. StreetInsider reported the note and the market reaction was modest, with a 1.03% intraday rise of $0.30 around the update source.
VRDN analyst rating: Evercore ISI maintains Outperform and adds VRDN to TAP list
Evercore ISI on February 26, 2026 kept an Outperform rating and added Viridian to its TAP list, signaling ongoing confidence in clinical and commercial prospects. The note arrived earlier the same morning and StreetInsider covered the move, which coincided with a 0.91% stock uptick of $0.26 source.
What the VRDN analyst rating changes mean for investors
Maintained ratings with a raised $45 price target mean analysts expect value from upcoming data and execution, not a new catalyst. Investors should read these as steady endorsements; Jefferies increased target price without changing its Buy call. That nuance suggests conviction on upside potential while acknowledging remaining clinical and commercial risks.
Price targets, market context, and historical coverage for VRDN
The $45 target from Jefferies now joins Evercore’s positive stance and highlights growing analyst attention for Viridian. Viridian’s market cap is about $2,393,999,527, and coverage has expanded from a handful of boutique firms to larger houses like Jefferies and Evercore over recent years. Historically, analyst views on VRDN have tracked trial readouts and partnership news; maintained positive ratings now put emphasis on upcoming milestones.
Risks, catalysts, and trading implications of the VRDN analyst rating moves
Ratings maintained rather than upgraded reduce the chance of a sharp sentiment reversal but keep upside tied to clinical outcomes and commercialization paths. Key catalysts include trial data, regulatory steps, and partner updates. Investors should weigh analyst optimism against biotech volatility and the company’s cash runway when sizing positions.
Meyka perspective and Meyka AI grade for VRDN
Meyka AI rates VRDN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. As an AI-powered market analysis platform, Meyka notes the maintained Buy and Outperform calls point to steady analyst conviction but not guaranteed upside. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
The VRDN analyst rating picture on February 26, 2026 is one of reinforced confidence rather than fresh upgrades. Jefferies kept a Buy and lifted its price target to $45, while Evercore ISI maintained Outperform and added Viridian to its TAP list. For investors, the message is clear: analysts expect value in upcoming milestones but are not signaling a dramatic change in risk profile. The company’s $2,393,999,527 market cap and recent modest intraday gains of $0.26 and $0.30 show the market is reacting but not pricing in a blowout result. Watch next clinical readouts, cash position, and partnership news closely. Use analyst notes as one input, consider the B+ Meyka AI grade, and size positions against biotech volatility and your risk tolerance.
FAQs
What exactly changed in the VRDN analyst rating on February 26, 2026?
Jefferies maintained a Buy and raised its price target to $45 on February 26, 2026. Evercore ISI maintained an Outperform rating and added VRDN to its TAP list the same day. Both actions reinforced positive analyst sentiment.
How should investors interpret the Jefferies $45 VRDN price target?
A $45 target reflects Jefferies’ view of Viridian’s clinical and commercial potential. It signals upside from current levels but is conditional on trial outcomes, regulatory progress, and execution. Use it alongside fundamentals and risk appetite.
Does the VRDN analyst rating change mean immediate price movement?
Maintained positive ratings typically spur modest moves, not big swings. On February 26, 2026, VRDN rose $0.30 and $0.26 around each note. Larger moves usually require new data or surprises.
How does Meyka view the VRDN analyst rating and stock grade?
Meyka AI rates VRDN B+, reflecting relative strength versus benchmarks and analyst consensus. Meyka views maintained Buy and Outperform calls as supportive but not definitive. This grade is informational and not financial advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.